Kantarjian and colleagues assigned 326 patients with relapsed or refractory ALL to receive either inotuzumab ozogamicin or a standard chemotherapy regimen. In an analysis of the fi rst 218 patients, 80.7% of individuals in the ADC arm had a complete remission (CR) with full or incomplete hematologic recovery, the latter meaning their blood counts didn't return to normal. In contrast, 29.4% of patients who received chemotherapy achieved these milestones. As a result, 41% of patients who received inotuzumab ozogamicin were able to have a stem cell transplant, versus 11% of those who received chemotherapy.
For the entire group of 326 patients, the median progression-free survival was 5 months for the inotuzumab ozogamicin arm and 1.8 months for the standard chemotherapy arm.
Side effects of the ADC included blockage of small veins in the liver, a potentially fatal complication.
Because many patients with AML are older, they can't tolerate aggressive chemotherapy and instead receive hypomethylating agents, which are less likely to produce remissions. Amir Fathi, MD, of Harvard Medical School in Boston, MA, reported data from a phase I study of vadastuximab talirine (Seattle Genetics) in 53 patients who received the CD33-targeting ADC in combination with the hypomethylating agents azacitidine or decitabine as fi rst-line therapy.
Among 49 evaluable patients, 41% had CRs and 30% had CRs with incomplete hematologic recovery. The median relapse-free survival was 7.7 months. Adverse events were mainly hematologic, with 45% of patients developing febrile neutropenia, for instance, and 53% developing thrombocytopenia. Overall, vadastuximab talirine plus a hypomethylating agent "is a highly promising combination that requires further study," Fathi says.
For Mark Litzow, MD, of the Mayo Clinic in Rochester, MN, who wasn't involved with either study, "it's very exciting to see the complete remission rate is 80%" in the ALL trial. Vadastuximab talirine plus hypomethylating agents also has potential against AML, he says. "I think this is impressive early data." -Mitch Leslie ■ instance, patients at SCI are assigned a professionally trained multidisciplinary care coordinator to help them navigate the many decisions related to cancer treatment, which are otherwise complex and often overwhelming.
Patients at SCI can also "detail their concerns right into their electronic medical records prior to their appointments, so physicians can review them in advance and be prepared to address them," Mitchell says. "It's another tangible way to involve people in their own care."
Comprehensive status, and the increased funding it can attract, will enable SCI to continue developing its programs in early-phase clinical research, immunotherapy, and genomics and precision medicine. In addition, "Stanford has a history of innovation in data management and analysis," Mitchell adds, so it is well positioned to help achieve an important goal of the National Cancer Moonshot-fi nding ways to merge myriad types of medical data. -Janet Colwell and Alissa Poh ■
ADCs Show Promise in Leukemias
Two investigational antibody-drug conjugates (ADC) have shown positive results against acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML), according to study results presented during the 21st Congress of the European Hematology Association in Copenhagen, Denmark, in June.
Patients with relapsed or refractory ALL typically have to achieve a complete remission before receiving an allogeneic stem-cell transplant, the only potential cure. 
NOTED
In vitro fertilization (IVF) is not associated with an increased risk of breast cancer compared with other fertility treatments, according to a recent study (JAMA 2016; 316:300-12) . Because IVF procedures temporarily cause changes in hormone levels, it had been thought that IVF might influence breast cancer risk. However, in this study of 25,108 women, there was no significant difference in breast cancer incidence, which was 3% for the IVF group and 2.9% for the non-IVF group after a median follow-up of 21 years.
The U.S. Preventive Services Task Force announced that it doesn't have enough evidence to recommend visual screening for melanoma in patients with no known special risk factors for the disease (JAMA 2016; 316:429-35 ).
Asuragen's molecular diagnostic QuantideX qPCR BCR-ABL IS kit received FDA clearance for monitoring response to therapies such as imatinib (Gleevec; Novartis) in the treatment of patients with chronic myeloid leukemia (CML). The Austin, TX, company said that its product is the first FDA-cleared diagnostic kit for use in CML management.
Gene variants associated with red hair, pale skin, and freckles are linked to a higher number of genetic mutations in skin cancers (Nat Commun 2016 July 12). The burden of mutations associated with these variants is comparable to an extra 21 years of sun exposure in people without the variants. Even a single copy of a red hairassociated MC1R gene variant increases the number of mutations in melanoma.
The NCI launched the Breast Cancer Genetic Study in African-Ancestry Populations initiative to explore genetic and biological factors that contribute to breast cancer risk among black women.
Researchers reported finding the earliest known case of cancer, an osteosarcoma, in a toe bone of a human ancestor estimated to have lived 1.7 million years ago; the diagnosis was possible thanks to advances in 3-dimensional imaging (S Afr J Sci 2016;112:100-4). The bone was found in a cave in South Africa.
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